Malignant Mesothelioma Therapeutics Pipeline Analysis - Clinical Trials & Results, Collaboration and Other Developments

Malignant mesothelioma is a rare type of cancer that is characterised by tumor formation in the mesothelium, a tissue layer that covers the pleural organs such as heart, abdomen, lungs and other organs. The biggest risk factor of the disease is exposure to asbestos, a silicate mineral. Some of the major symptoms of the disease include cough, shortness of breath and pain in the chest. The symptoms in malignant mesothelioma could take as long as 30 to 50 years to show. Surgery, chemotherapy and radiotherapy are some of the major options available for the treatment of malignant mesothelioma. The prevalence of the disease is not known; however, it is estimated that malignant mesothelioma accounts for approximately 1% of all cancers globally. According to the cancer research, in the U.K., 48% cases of malignant mesothelioma are of people above the age of 75 years.

Explore Report at: https://www.psmarketresearch.com/market-analysis/malignant-mesothelioma-therapeutics-pipeline-analysis

The therapeutics pipeline for malignant mesothelioma is expected to witness considerable growth in the near future on account of increasing exposure of general population to pollutants such as asbestos as a result of rising level of pollution in the environment, eventually leading to increasing prevalence of the disease. Other factors that are expected to contribute to the growth in the therapeutics pipeline of malignant mesothelioma include poor prognosis of the disease, growing healthcare investment on cancer treatments and rising geriatric population.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/malignant-mesothelioma-therapeutics-pipeline-analysis/toc-sample

Some of the major players involved in the development of therapeutics for the treatment of malignant mesothelioma include AstraZeneca plc, Boehringer Ingelheim GmbH, Polaris Pharmaceuticals, Inc., PharmaMar S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Co., Ltd., Bayer AG, Aduro Biotech, Inc., Calithera Biosciences, Inc., CBT Pharmaceuticals, Inc.

Critical Limb Ischemia Therapeutics Pipeline Analysis 2017

Critical limb ischemia (CLI) is a severe peripheral arterial disease (PAD) characterised by blockage in the arteries of the lower limbs, which in turn reduces blood-flow. The primary cause of the disease is atherosclerosis or the buildup of fatty deposits called plaque in the arteries. Other risk factors for the disease include hypercholesterolemia, obesity, smoking, hypertension and diabetes. Diabetes is a significant risk factor because it is often linked with severe PADs. The most common symptoms of CLI are the ischemic rest pain — extreme pain or hard to heal sores on the feet or legs. CLI is associated with high risk for cardiovascular events, including myocardial infarction and in some cases death due to CLI. Auscultation, ankle-brachial index (ABI), magnetic resonance angiography (MR angiography), doppler ultrasound, CT angiography and angiogram are some of the tools to diagnose CLI. Treatment of the disease include medications for pain relief, endovascular treatments such as angioplasty, stents, laser atherectomy, directional atherectomy and surgical treatments such as amputation of the limb.

Explore Report at: https://www.psmarketresearch.com/market-analysis/critical-limb-ischemia-therapeutics-pipeline-analysis

Considerable growth is expected in the therapeutics pipeline for CLI in the near future mainly due to rising old-age population, increasing incidence of CLI and its risk factors such as diabetes and obesity. Increasing investment by companies for the research and development of drug candidates for the treatment of CLI is also a major factor driving the growth of pipeline of CLI therapeutics, globally. Lack of an approved treatment for the disease is one of the key factors encouraging companies to invest in the research and development of therapeutics for the treatment of CLI.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/critical-limb-ischemia-therapeutics-pipeline-analysis/toc-sample

Some of the major players involved in the development of drugs for CLI include Caladrius Biosciences, Inc., Boston Scientific Corporation, Rexgenero Limited, Reven Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Anesiva, Inc., Taiwan Bio Therapeutics Co., Ltd., Beike Biotech India Pvt. Ltd., Pharmicell Co., Ltd., United Therapeutics Corporation, Stempeutics Research Pvt. Ltd.

Acute Kidney Injury Therapeutic Pipeline Analysis, 2017 - Designation, Collaboration and Other Developments

Acute kidney injury therapeutic pipeline is likely to grow on account of increasing incidence of diabetes and high blood pressure, in people, resulting in increasing prevalence of acute kidney injury, globally. Low market penetration, due to presence of limited number of companies making an analog and increasing health awareness among people are few other factors contributing to the growth of acute kidney injury therapeutic pipeline. According to the Centers for Disease Control and Prevention, women (15.93%) are more likely to have stages 1 to 4 of acute kidney injury than men (13.52%). It is also more common among African Americans (17.01%) and Mexican Americans (15.29%) than in Caucasians (13.99%).

Explore Report at: https://www.psmarketresearch.com/market-analysis/acute-kidney-injury-therapeutic-pipeline-analysis

Acute kidney injury is a serious condition which includes kidney damage or failure. This results in building up of waste products in blood, due to which the balance of fluids in the body gets disturbed, in turn affecting several other organs including heart, lungs and brain. Acute kidney injury is caused due to the slow flow of blood due to conditions such as low blood pressure, allergic reactions, organ failure, heart diseases, blood loss and overuse of medicines. Sepsis, cancer, vasculitis, interstitial nephritis, scleroderma and glomerulonephritis cause direct damage to kidney which can also result in the development of acute kidney injury. Blockage of urinary tract due to several conditions such as kidney stones or blood clots in the tract can also result in acute kidney failure. The most common signs and symptoms of acute kidney injury include nausea, shortness of breath, swelling in legs and around eyes, less urination, fatigue and chest pain. Acute kidney injury is diagnosed by measuring the urine output, measuring glomerular filtration rate, blood tests, urine tests, imaging tests and kidney biopsy. Acute kidney injury is treated by treating the root cause of the disease in an individual. Severe cases require dialysis to improve kidney function until the kidneys do not recover or are transplanted.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/acute-kidney-injury-therapeutic-pipeline-analysis/toc-sample

Some of the leading companies having a pipeline of acute kidney injury therapeutics include Baxter Healthcare Corporation, Angion Biomedica Corp., AM-Pharma BV, Sentien Biotechnologies, Inc., F. Hoffmann-La Roche Ltd., Evotec AG, NephroGenex, Inc., G1 Therapeutics, Inc., Alloksys Life Sciences BV, DiaMedica Therapeutics, Inc.

Psoriasis Therapeutic Pipeline Analysis 2017 - Clinical Trials & Results and Other Developments

Therapeutic pipeline for analysis of psoriasis is likely to grow on account of increasing prevalence of psoriasis, globally, which is caused due to abnormalities in the immune system caused by external stressors and low market penetration of drugs that can successfully cure the disease. According to the latest data published by the American Academy of Dermatology, approximately 7.5 million people in the U.S. are suffering from psoriasis. The disease is prevalent in people of all age groups, mostly in adults. Both males and females are equally susceptible to this disease.

Explore Report at: https://www.psmarketresearch.com/market-analysis/psoriasis-therapeutic-pipeline-analysis

Psoriasis is a serious condition which includes chronic inflammation and scaling on the skin. Psoriasis develops when skin cells rapidly grow below the surface of the skin and get deposited on the surface before they get mature. Usually this process takes about a month, but in psoriasis it may occur in a few days. Psoriasis leads to the development of thick patches of inflamed skin with a silvery scale covering. These patches are also referred to as plaques and they itch or feel sore. They mostly occur on knees, elbows, other parts of the legs, lower back, scalp, soles of the feet, face and palms. Psoriasis can also affect the toenails, the fingernails, inside the mouth and the soft tissues of the genitals. Pain and itching may interfere with basic functions such as self-care, sleep and walking. Psoriasis is caused when T cells accidently get involved and become active to the extent of triggering other immune responses, thus, resulting in inflammation and rapid turnover of skin cells. Another major source of developing psoriasis is its presence in the family history of an individual. Psoriasis is diagnosed by examining a small skin sample from a patient, under a microscope. There are several forms of psoriasis including guttate psoriasis, plaque psoriasis, erythrodermic psoriasis, inverse psoriasis, pustular psoriasis and psoriatic arthritis. The treatment of psoriasis includes topical treatment, phototherapy and systemic therapy. Topical treatment includes application of ointment or cream forms of corticosteroids, vitamin D3, retinoids, coal tar, or anthralin. Phototherapy includes exposure of UV light in controlled conditions, while systemic treatment includes retinoids, cyclosporine, methotrexate, PDE4 inhibitors and biologic response modifiers medicines.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/psoriasis-therapeutic-pipeline-analysis/toc-sample

Some of the leading companies having a pipeline of psoriasis therapeutics include Novartis AG, UCB S.A., Pfizer, GlaxoSmithKline plc, Betta Pharmaceuticals Co., Ltd., AbbVie, Inc., Eli Lilly and Company, Santalis Pharmaceuticals, Inc., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc.

Nephrotic Syndrome Therapeutics Pipeline Analysis - Collaboration and Other Developments

The growth in the pipeline of nephrotic syndrome is attributed to the increase in prevalence of individuals affected with diabetes, hypertension and hyperlipidaemia. Unhealthy lifestyle and unhygienic crops and fruits are also the factors that are contributing to the growth of therapeutic pipeline of nephrotic syndrome. Environmental factors are also thought to be responsible for occurrence of nephrotic syndrome. Funds from various organizations are contributing to the research and developments in the therapy area which in turn is believed to help in early diagnosis of the disease.

Explore Report at: https://www.psmarketresearch.com/market-analysis/nephrotic-syndrome-therapeutics-pipeline-analysis

Nephrotic syndrome is a collection of symptoms such as, proteinuria, hyperlipidemia, edema or swelling and hypoalbuminia, which mainly affects kidneys. Edema is caused when albumin leaks into the urine and body loses its capacity to absorb its extra fluid. The anomalies in kidney filters, glomeruli, is the main risk factor of nephrotic syndrome. Tiny blood vessels in glomeruli removes waste and excess fluid from blood and direct them to urinary bladder in the form of urine. Nephrotic syndrome can also be caused by metabolic disease such as diabetes and lupus. Weight gain, fatigue, foamy urine and loss of appetite are the main symptoms observed in patients with nephrotic syndrome. Complication associated with nephrotic syndrome are hypothyroidism, anemia, coronary artery disease or coronary heart disease, high blood pressure or hypertension and acute kidney injury.

In 2014, Anthera Pharmaceuticals, Inc. and Zenyaku Kogyo Co., Ltd. of Japan entered a license agreement, under the terms of which Zenyaku Kogyo Co., Ltd. got the rights for the development and commercialization of subcutaneous blisibimod in Japan and potentially in other Asian countries. In October 2014, the National Institutes of Health announced to provide funding of $5.8 million over a five-year period to the Nephrotic Syndrome Study Network, also known as NEPTUNE.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/nephrotic-syndrome-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of nephrotic syndrome therapeutics include, F. Hoffmann-La Roche AG, Asahi Kasei Pharma Corporation, Mallinckrodt LLC, Novartis AG, Bristol-Myers Squibb Company, Genentech, Inc., Bellus Health Inc., GlaxoSmithKline plc, Retrophin, Inc., Concert Pharmaceuticals Inc.

Ankylosing Spondylitis Therapeutics Pipeline Analysis 2017 by P&S Market Research

Ankylosing spondylitis is an idiopathic disease, associated with HLA-B27, IL23R and ERAP1 genes. Usually, fewer people get affected with ankylosing spondylitis irrespective of activation of genes. Blood test, X-ray test, Magnetic Resonance Imaging (MRI) and physical investigations are some of the ways to effectively diagnose the disease. The disease begins with the inflammation in joints in the vertebrae and pelvic bones and spine. The environmental factors are believed to be the most important risk factor for increasing the incidence of the disease. The primary symptoms include back pain and stiffness.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis

Considerable growth in therapeutic pipeline of ankylosing spondylitis is attributed to the increase in prevalence of the disease among teens as well as young adult patients. Researchers have not been able to identify the actual cause of the disease. Novel anti-inflammatory agents and pain killers are being developed that are primarily responsible for the growth of therapeutics pipeline for ankylosing spondylitis.

In June 2015, UniQuest Pty Ltd signed a collaborative agreement with Janssen Cilag Pty Limited for development and commercialization of small molecule modulators of a biological target identified by the University of Queensland, as an important factor for the treatment of ankylosing spondylitis, and potentially psoriasis and inflammatory bowel disease. In December 2016, Janssen Biotech, Inc. confirmed the submission of two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA (golimumab) for the treatment of patients with psoriatic arthritis as well as ankylosing spondylitis. SIMPONI ARIA is fully humanised anti-tumour necrosis factor alpha therapy.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of ankylosing spondylitis therapeutics include, AbbVie Inc., Sanofi SA, Centocor Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Janssen Research & Development, LLC, Novartis AG, Amgen plc,  Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp., Galapagos NV, Celgene Corporation,  Shanghai Pharmaceuticals Holding Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Pfizer Inc., UCB Pharma SA, Eli Lilly and Company, Eisai Co., Ltd., Korea Otsuka Pharmaceutical Co., Ltd., Inflexxion Inc. and Johnson & Johnson Pvt. Ltd.

Cataract Therapeutics Pipeline Analysis, Designation, Collaboration and Other Developments

Cataract is the clouding of eye lens and it can occur in either one or both the eyes. Cataract is generally more common among people over 80 years of age. According to the National Eye Institute, more than half of the Americans suffer from cataract. Eye lens is transparent and light sensitive and is located at the back of the eye. It helps to focus light rays on retina which aids in the formation of clear image. Images at retina are converted into optic signals that are then communicated to the brain. Eye lens is made up of protein and water, but as a person grows old, the protein of the lens clump together and starts to form a cloud which continues to grow, time making it harder for patients to see. Cloud formation in eye lens is the characteristic feature of cataract. In people affected by cataract, colour of eye lens also changes to brownish, adding a brownish tint to their vision.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cataract-therapeutics-pipeline-analysis

Considerable growth in therapeutic pipeline of cataract is expected in the future which could be attributed primarily to the increasing prevalence of cataract. According to researchers, smoking and diabetes are considered to be the major causes of cataract disease. Consumption of unhygienic crops and fruits, unhealthy lifestyle and rising level of pollutants in the environment are some of other important factors responsible for increasing incidence of cataract disease.

In September 2016, Johnson & Johnson Pharmaceutical Ltd. entered into an agreement with Abbott Medical Optics Inc. (AMO) to acquire for the wholesome amount of $4.325 billion. AMO’s reported sales were around $1.1 billion for the year 2015. The acquisition also included accession of ophthalmic products in three business segments such as, cataract surgery, laser refractive surgery and consumer eye health. In March 2016, Acucela Inc. and YouHealth Eyetech Inc. signed an agreement of license on lanosterol technology for the non-surgical pharmacologic treatment of cataracts.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cataract-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of cataract therapeutics include, Allergan plc, Genentech, Inc., Aqumen Biopharmaceuticals, N.A., Reata Pharmaceuticals, Inc. Bausch & Lomb Incorporated, Omeros Corporation, Chakshu Research, Inc., Santen Pharmaceutical Co., Ltd., Eyegate Pharmaceuticals, Inc., Icon Bioscience Inc., Othera Pharmaceuticals Inc., Xigen SA, Regeneron Pharmaceuticals Inc., ESBATech AG, Valeant Pharmaceuticals International, Inc., Ivantis, Inc., Eyetech Pharmaceuticals Inc., Ocular Therapeutix, Inc., Merck Sharp & Dohme Corp., Dompé Farmaceutici S.p.A, Sirion Therapeutics, Inc., Croma-Pharma GmbH, Kala Pharmaceuticals, Inc. and Amgen plc.